Lumateperone

Lumateperone
Clinical data
Pronunciation	/ˌluːməˈtɛpəroʊn/; LOO-mə-TE-pər-ohn
Trade names	Caplyta
Other names	ITI-007; ITI-722
AHFS/Drugs.com	Monograph
MedlinePlus	a620014
License data	US DailyMed: Lumateperone;
Routes of; administration	By mouth
Drug class	Atypical antipsychotic
ATC code	N05AD10 (WHO) ;
Legal status
Legal status	US: ℞-only;
Pharmacokinetic data
Bioavailability	4.4%
Protein binding	97.4%
Metabolism	Multiple UGTs, CYP450s, and AKR enzymes
Excretion	<1% excreted unchanged in urine
Identifiers
	IUPAC name 1-(4-fluorophenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-butanone;
CAS Number	313368-91-1 ;
PubChem CID	9821941;
DrugBank	DB06077;
ChemSpider	7997690;
UNII	70BSQ12069;
KEGG	D11169;
Chemical and physical data
Formula	C24H28FN3O
Molar mass	393.506 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN1CCN2c3c(cccc31)[C@@H]1CN(CCCC(=O)c3ccc(F)cc3)CC[C@@H]12;
	InChI InChI=1S/C24H28FN3O/c1-26-14-15-28-21-11-13-27(16-20(21)19-4-2-5-22(26)24(19)28)12-3-6-23(29)17-7-9-18(25)10-8-17/h2,4-5,7-10,20-21H,3,6,11-16H2,1H3/t20-,21-/m0/s1; Key:HOIIHACBCFLJET-SFTDATJTSA-N;

Lumateperone, sold under the brand name Caplyta, is an atypical antipsychotic medication of the pyridopyrroloquinoxaline and butyrophenone families. It is approved for the treatment of schizophrenia as well as bipolar depression, as either monotherapy or adjunctive therapy (with lithium or valproate), and for major depressive disorder as an adjunctive therapy only (with an oral antidepressant). It is developed by Intra-Cellular Therapies, licensed from Bristol-Myers Squibb. Lumateperone was approved for medical use in the US in December 2019 with an initial indication for schizophrenia. It became available in February 2020.